Member Info for Arbitrader75

The retail part has been sold for a little over 7 million.

1. Takeda will be disciplined in its approach to the Shire acquisition (in finances, purchase price, etc.). 2. This possible acquisition is just one option being considered to achieve the Vision 2025 strategy and does not represent a change in strategy. Takeda has sensed some confidence in the progress it has made thus far toward achieving the Vision 2025 strategy. 3. Acquisition of Shire would allow Takeda to achieve the Vision 2025 strategy sooner. The two companies are a good fit in sales by field and country or region. For example, 30% of Takeda�s pipeline drugs are for rare diseases, so there are good synergies. 4. Takeda is exploring the acquisition of the entire company (Shire plc) and is not considering purchasing only some businesses or assets. 5. Takeda is not exploring this possibility simply for tax savings through a tax inversion or head office relocation. The goal would only be to become a global pharma business that is based in Japan. 6. Takeda is looking to maintain its current credit rating (e.g., Moody�s Japan A1). No change will be made in the dividend policy (�180 DPS). 7. In financial discipline, Takeda indicated that even if the net debt/EBITDA multiple rose above 3x over the near term (currently at approx. 1.8x for Takeda), Takeda would work to quickly bring this down to around 2x. 8. Takeda will make an announcement in accordance with the UK�s Panel on Takeovers and Mergers regulations by 5:00 p.m. on 25 April (UK time) and will announce by the same date whether it will submit an offer for Shire.

Credit Suisse reports Takeda ceo saying: to be disciplined in shire m&a approach. Shire deal just one option being considered.

doesn't intend to make offer for Faroe

completes purchase of matthew clark bibendum

https://news.sky.com/story/2600-jobs-at-risk-as-bargain-booze-heads-for-administration-11307294

CVR is said close to administration.

The Japanese are surely not big enough for the cash bid everybody's dreaming off. Even around 40 it would have to be a sort of merger, so getting stock in a company without a listing in europe. Anyone fancy that? I'm not in any case. Sure you may hope it will flush out another bidder, with Pfizer pretty much being the only one, but those easy targets of mid to high 50's are, for now, way too optimistic.

Odey ups stake in PLUS

TCM investigated for the august 2017 figures

We have updated our forecasts to reflect the higher interest cost (�56m in FY18E, �70m thereafter), increased cost of bonding and assume that all warrants are exercised, reducing our FY18E/FY19E earnings forecasts by 55%/60%. We acknowledge that these forecasts contain a high degree of uncertainty and may well change again materially post-strategy update. Whilst the picture remains unclear and any operational recovery is unlikely to be linear, we upgrade to Buy with a 130p target price, valuing the group on 6.5x FY18E EBITDA, before deducting net debt and the pension deficit and dividing by 182m shares, which assumes all warrants are exercised. The agreement with lenders reduces near-term uncertainty on financing, and implies no further material downside from EfW or the wider contract review, two key areas of concern. It also suggests the lenders will allow the group time in implementing a solution to structurally reduce its net debt.

Wow you really are a gullible one aren't ya.

CVR cancels the interim div of 4.5p

Well shit, the bs keeps coming out

The SEC has nothing to do with this company.

new rns out

still, if they have so much confidence in the company and the regulation outcome, why are they selling now? surely when the dust has settled there will be a rerate.

Streetinsider reports they have been approached for a takeover

Overall, the settlement should draw a line under the sand and help focus on the underlying business which not so long ago delivered RoE of c35%. We forecast FY2019E RoTE will recover to 25.8% (up from 12% in FY2017).

We view today�s public drawing of a line in the sand as positive. Shareholders, and prospective investors, may now get back to appraising the group�s activities on an ongoing basis with full scope to make an informed investment decision. In future, the group aims to achieve a ~10% RoA (Return on Assets) with receivables growth for the group of between 5-10% through the cycle and a targeted dividend cover of ~1.4x (70% payout ratio). So, the receivables book will be smaller as a result of the home credit changes but, importantly, the group will move down the risk spectrum as it targets more sustainable growth whilst still generating a good RoA and providing stable returns to shareholders.